CD274 and lymphoma: In conclusion, the results of our meta-analysis indicate that PD-1 pathway-blocking agents are a promising novel therapy for lymphoma and that PD-L1 may be a candidate molecular marker for the identification of patients who may benefit the most from PD-1-blockade therapy.